PharmaTimes - April 2016

As we are a pretty opinionated bunch here at PharmaTimes, we like it when contributors are prepared to stand up and express a viewpoint. For the past few months, our expanded SmartViews section has featured thought-leading articles on a wide range of topics – from patient-centricity and merger mania to drug pricing and product launch strategy – and this month is no exception.

In SmartViews, we offer articles on topics as diverse as the dangers of Brexit, a crisis in pharmacy, the impact of new EU clinical trial regulations and yet more threats to pharma’s reputation.

Also in this issue, in Time to Think Rare, we continue our in-depth look at the challenges and opportunities in rare diseases, this month asking what patients need and how pharma can help.

Going ‘beyond the pill’ is a major trend in the industry yet many companies focus solely on digital innovation. In Outside the Box, we explore how the packaging and formulation of a medicine can boost sales – but only if you listen to patients first.

Translating great science into the next generation of life-changing medicines requires a leap of faith but pharma companies are getting a helping hand. In Care Package, we feature three organisations that are building early stage projects for pharma to take to market.

Hugh Gosling, Editor

April 2016 - magazine highlights

SmartViews: In Perfect Harmony

Although the new EU clinical trials regulation is not due...

SmartPeople: Under the skin

Integrating patient insight into the business is a key ele...

SmartPeople: Efficiency savings

As one of the most efficient markets in Europe, the UK's g...

Loud and clear

For pharma companies brave enough to stick their head abov...

Care package

Creating the next generation of life-changing medicines ha...

Outside the box

Going 'beyond the pill' is a major trend in pharma today,...

Time to think rare

Rare diseases are starting to gain the recognition they de...

SmartViews: Pharmacy in crisis

The UK Government's austerity eye has turned on community...

SmartViews: The big leap?

The chasm between industry and academia is shrinking, with...

SmartViews: Race to trace

The EU prescription medicine supply chain is changing radi...

SmartViews: Staying power

While opinion polls are evenly split in the 'Brexit' refer...

Patient files: Prostate cancer

Ten years ago, Hugh Gunn was diagnosed with advanced prost...